CCL5 and neoplasm: In agreement with previous reports, patients in our study with higher CCL5 base levels and higher CCL5 induction fold may benefit from VT1021 treatment via CCL5’s role to promote antitumor immunity by recruiting anti-tumor T cells and dendritic cells to the TME, thus enhancing the immunotherapy response to inhibit tumor growth53–56.